IL6 and neoplasm: This enhances the infiltration of effector T cells (CD4+ and CD8+ T cells) into the tumor, promoting the release of pro-inflammatory cytokines (TNF-α, IL-6, and IL-12), killing the cancer and reversing tumor resistance.